Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
about
Effects of Alcohol on Tumor Growth, Metastasis, Immune Response, and Host SurvivalTherapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advancesAndrogen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayImmune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.Sex hormones have pervasive effects on thymic epithelial cells.A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer modelVaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.AR Signaling in Breast Cancer.Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Prostate cancer vaccines: the long road to clinical application.Overview on the complexity of androgen receptor-targeted therapy for prostate cancerIntegrating Immunotherapies in Prostate Cancer.The role of TWIST1 in epithelial-mesenchymal transition and cancers.Immunotherapy of Prostate Cancer: Facts and Hopes.Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.Therapeutic vaccines for prostate cancer: recent advances and future directions.Prospects for the future of prostate cancer vaccines.MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines.Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing TwistEarly evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.Targeting the androgen receptor in triple-negative breast cancer: current perspectives.STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer.Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.Perspectives on the clinical development of immunotherapy in prostate cancer.Androgen deprivation and immunotherapy for the treatment of prostate cancer
P2860
Q26773212-AFE2D084-EF52-4227-B6BE-59C3F4CCDE27Q26827475-3B2AADEE-5648-4449-9965-0A82C96C5973Q34444867-F62F82CA-70E4-4C32-A643-97D70DCDCC00Q34458617-BD708C0B-3201-4F58-95BA-2FE1D41AED6EQ34537725-A1DC4DC3-46AC-49C3-A8CE-35C158D55511Q34687216-80343355-27A1-4A3F-B2F9-CEF0B1C06B80Q35799330-CD144DFA-201D-4CC2-8EB8-1175F63A0D5FQ35926133-B1B85245-CC32-4A2D-AD02-91ED5652C1CCQ36414022-B28BB52F-04AB-4C7A-973B-DAA0B3B9E38FQ36420021-0FED94E3-D08B-48FC-BEF9-CD2C083B04A4Q37269053-0A0DCA44-12B5-4209-9878-0F9A376EE84DQ37515914-D483E1E4-73FF-4DD2-B4E7-E4AEDBEA1AB0Q37721492-127F4DDF-F577-44C8-9853-25DE6AB7AD34Q38207592-71FCCE88-3A59-444E-A5EB-E909CF3740B6Q38254639-5295FD42-732A-4F4D-A9D1-C91CB4493517Q38359237-6491320B-52B1-4001-9763-CFCFF5222F1BQ38364166-C21E07CC-377F-479B-8E50-49C0CF7025BCQ38567067-B768954C-9B8B-46A1-95C3-F2E246E8B966Q38646345-C2E4F0C1-188F-40EF-B0C2-1E0B5574C61BQ38664882-2F272366-E3F5-44AD-9FA5-D524D9E970B9Q38780080-9164946B-44C9-4F49-9050-CD1C6CDE4DA0Q38906558-3A94175A-48B6-45DF-A539-CFAACD38ED2AQ38943601-408E38E9-143C-48FF-8D1E-FF72F9F2C46DQ38962923-DFC5BD59-04DF-4D60-86C6-108A88918976Q40801573-8527DD0E-61AA-47C3-B233-0A2E1D10E31BQ41686942-390930E9-5C9B-45C6-807F-7188456850C4Q42324670-A5A40D57-0DAF-47D3-8C79-A05F825F2652Q42364449-72BA73A1-01C4-42A4-955F-B64FB75C75B9Q47110097-AA177871-EFB2-4BE3-A0B7-C2AEF5841DEEQ47757361-D7D676B5-7486-4C45-A80E-5986CC544270Q48229904-6AFDED2E-AF4B-44A4-A64C-B0A39BA79A10Q55029444-D8461318-935D-4F78-914C-41C5237445DFQ57115565-52F3D14F-BA4C-42A2-AFE2-877AF15C6774
P2860
Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination therapy with a sec ...... taneous prostate cancer model.
@en
Combination therapy with a sec ...... taneous prostate cancer model.
@nl
type
label
Combination therapy with a sec ...... taneous prostate cancer model.
@en
Combination therapy with a sec ...... taneous prostate cancer model.
@nl
prefLabel
Combination therapy with a sec ...... taneous prostate cancer model.
@en
Combination therapy with a sec ...... taneous prostate cancer model.
@nl
P2093
P2860
P1476
Combination therapy with a sec ...... ntaneous prostate cancer model
@en
P2093
Andressa Ardiani
Andy Protter
Connie J Rogers
David Apelian
James W Hodge
Thomas H King
Zhimin Guo
P2860
P304
P356
10.1158/1078-0432.CCR-13-1026
P407
P577
2013-09-18T00:00:00Z